title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
"The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK",20220616T140943,https://www.benzinga.com/general/biotech/22/06/27737919/the-daily-biotech-pulse-roches-alzheimers-drug-fails-advisors-back-pfizer-moderna-shots-for-young,EXEL,0.147607,Neutral,0.003742
"The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs",20220503T130106,https://www.benzinga.com/general/biotech/22/05/26958446/the-daily-biotech-pulse-fdas-adcomm-for-acadias-pimavanserin-review-issues-for-speros-tebipenem-a,EXEL,0.093507,Neutral,0.001098
"Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar",20240111T220100,https://www.prnewswire.com/news-releases/gastroenteropancreatic-neuroendocrine-tumors-market-to-showcase-a-significant-growth-by-2032-evaluates-delveinsight--key-players---eli-lilly-and-company-phanes-therapeutics-camurus-ab-advanced-accelerator-applications-pharma-302032286.html,EXEL,0.075318,Neutral,0.041398
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period  ( 2019-2032 )  | DelveInsight,20231121T220100,https://www.prnewswire.com/news-releases/colorectal-cancer-treatment-drug-market-to-show-immense-growth-during-the-study-period-20192032--delveinsight-301994315.html,EXEL,0.023102,Neutral,-0.093525
"Earnings Scheduled For May 10, 2022",20220510T091808,https://www.benzinga.com/news/earnings/22/05/27099859/earnings-scheduled-for-may-10-2022,EXEL,0.015162,Neutral,9e-06
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths' - Macrogenics  ( NASDAQ:MGNX ) ,20240510T190803,https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38768977/macrogenics-gets-downgraded-following-disappointing-prostate-cancer-trial-results-w,EXEL,0.183198,Somewhat-Bearish,-0.194098
EXEL: 3 Biotech Stocks Losing Momentum as March Ends,20230329T141736,https://stocknews.com/news/exel-mgnx-pbyi-incy-3-biotech-stocks-losing-momentum-as-march-ends/,EXEL,0.241684,Somewhat-Bullish,0.245302
